KZR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.310

-56.33%

-1.270

-36.5%

-1.255

-32.89%

Estimates Revision

The market is revising No Change the revenue expectations for Kezar Life Sciences, Inc. (KZR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 46.92%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-4.98%

In Past 3 Month

Stock Price

Go Up

+46.92%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast KZR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZR is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

3 Hold

0 Sell

Hold

Current: 0.000

Low

5.00

Averages

6.00

High

7.00

Current: 0.000

Low

5.00

Averages

6.00

High

7.00

Jefferies

Maury Raycroft

Buy -> Hold

downgrade

$18 -> $7

2025-10-17

Reason

Jefferies

Maury Raycroft

Price Target

$18 -> $7

2025-10-17

downgrade

Buy -> Hold

Reason

Jefferies analyst Maury Raycroft downgraded Kezar Life Sciences to Hold from Buy with a price target of $7, down from $18. The company announced it could not align with the FDA on a registrational path for zetomipzomib in autoimmune hepatitis, leading to a formal process to explore strategic alternatives, the analyst tells investors in a research note. The firm lowered the probability of sucess of zetomipzomib to 10% from 25% and downgraded the shares.

William Blair

Matthew Phipps

Outperform -> Market Perform

downgrade

2025-10-17

Reason

William Blair

Matthew Phipps

Price Target

2025-10-17

downgrade

Outperform -> Market Perform

Reason

William Blair analyst Matthew Phipps downgraded Kezar Life Sciences to Market Perform from Outperform without a price target. The company announced it has been unable to align with the FDA on a registrational trial for zetomipzomib in autoimmune hepatitis and is initiating a process to explore strategic alternatives, the analyst tells investors in a research note. The firm is surprised to see the FDA refusing to host a Type C meeting. Considering Kezar's current cash balance and liabilities, Blair believes a potential acquisition in the $6 to $7 per share range could be feasible.

Wells Fargo

Equal Weight

downgrade

$7 -> $5

2025-10-17

Reason

Wells Fargo

Price Target

$7 -> $5

2025-10-17

downgrade

Equal Weight

Reason

Wells Fargo lowered the firm's price target on Kezar Life Sciences to $5 from $7 and keeps an Equal Weight rating on the shares. The firm notes management reported it was unable to align with the FDA on a Phase 3 for zetomipzomib in autoimmune hepatitis, effectively killing the program. Wells thinks there could be upside if they return cash to shareholders or in a reverse merger scenario and why shares are trading up +45% post market.

Valuation Metrics

The current forward P/E ratio for Kezar Life Sciences Inc (KZR.O) is -1.24, compared to its 5-year average forward P/E of -3.73. For a more detailed relative valuation and DCF analysis to assess Kezar Life Sciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.73

Current PE

-1.24

Overvalued PE

0.05

Undervalued PE

-7.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

8.29

Current PS

0.00

Overvalued PS

24.12

Undervalued PS

-7.54

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KZR News & Events

Events Timeline

No data

News

9.0

01-09NASDAQ.COM

KZR Secures FDA Type C Meeting to Discuss Zetomipzomib Development

4.0

2025-10-17Benzinga

Jefferies Lowers Kezar Life Sciences Rating to Hold and Reduces Price Target to $7

9.0

2025-10-17Benzinga

Kezar Initiates Strategic Review Following FDA Setback on Liver Drug Development

People Also Watch

Frequently Asked Questions

What is Kezar Life Sciences Inc (KZR) stock price today?

The current price of KZR is 6.2 USD — it has decreased -4.62 % in the last trading day.

What is Kezar Life Sciences Inc (KZR)'s business?

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.

What is the price predicton of KZR Stock?

What is Kezar Life Sciences Inc (KZR)'s revenue for the last quarter?

Kezar Life Sciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Kezar Life Sciences Inc (KZR)'s earnings per share (EPS) for the last quarter?

Kezar Life Sciences Inc. EPS for the last quarter amounts to -1.53 USD, decreased -94.50 % YoY.

What changes have occurred in the market's expectations for Kezar Life Sciences Inc (KZR)'s fundamentals?

How many employees does Kezar Life Sciences Inc (KZR). have?

Kezar Life Sciences Inc (KZR) has 55 emplpoyees as of January 10 2026.

What is Kezar Life Sciences Inc (KZR) market cap?

Today KZR has the market capitalization of 45.40M USD.